메뉴 건너뛰기
The Lancet Oncology
Volumn 14, Issue 3, 2013, Pages 182-183
IGF-1R inhibition: Right direction, wrong pathway?
Author keywords

[No Author keywords available]
Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GANITUMAB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; RAS PROTEIN; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN RECEPTOR;
EID: 84875246481     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70019-6     Document Type: Letter
Times cited : (12)
References (10)
  • 1
    • 84863584930 scopus 로고    scopus 로고
    • Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment
    • Fagan DH, Uselman RR, Sachdev D, Yee D Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res 2012, 72:3372-3380.
    • (2012) Cancer Res , vol.72 , pp. 3372-3380
    • Fagan, D.H.1    Uselman, R.R.2    Sachdev, D.3    Yee, D.4
  • 2
    • 0036111682 scopus 로고    scopus 로고
    • Insulin-like growth factors and cancer
    • Furstenberger G, Senn HJ Insulin-like growth factors and cancer. Lancet Oncol 2002, 3:298-302.
    • (2002) Lancet Oncol , vol.3 , pp. 298-302
    • Furstenberger, G.1    Senn, H.J.2
  • 3
    • 4444370976 scopus 로고    scopus 로고
    • Mechanisms by which IGF-I may promote cancer
    • Grimberg A Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther 2003, 2:630-635.
    • (2003) Cancer Biol Ther , vol.2 , pp. 630-635
    • Grimberg, A.1
  • 4
    • 84875257995 scopus 로고    scopus 로고
    • Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
    • published online Feb 13.
    • Robertson JFR, Ferrero J-M, Bourgeois H, et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol 2013, published online Feb 13. http://dx.doi.org/10.1016/S1470-2045(13)70026-3.
    • (2013) Lancet Oncol
    • Robertson, J.F.R.1    Ferrero, J.-M.2    Bourgeois, H.3
  • 5
    • 77956227862 scopus 로고    scopus 로고
    • Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC)
    • abstr 7500.
    • Jassem J, Langer CJ, Karp DD, et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2010, 28(suppl). abstr 7500.
    • (2010) Proc Am Soc Clin Oncol , vol.28 , Issue.SUPPL.
    • Jassem, J.1    Langer, C.J.2    Karp, D.D.3
  • 6
    • 83255163333 scopus 로고    scopus 로고
    • R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study
    • Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011, 29:4541-4547.
    • (2011) J Clin Oncol , vol.29 , pp. 4541-4547
    • Pappo, A.S.1    Patel, S.R.2    Crowley, J.3
  • 7
    • 83455236504 scopus 로고    scopus 로고
    • Insulin-like growth factor: current concepts and new developments in cancer therapy
    • King ER, Wong KK Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent Pat Anticancer Drug Discov 2012, 7:14-30.
    • (2012) Recent Pat Anticancer Drug Discov , vol.7 , pp. 14-30
    • King, E.R.1    Wong, K.K.2
  • 8
    • 77950691907 scopus 로고    scopus 로고
    • Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines
    • Chakraborty AK, Welsh A, Digiovanna MP Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines. Breast Cancer Res Treat 2010, 120:327-335.
    • (2010) Breast Cancer Res Treat , vol.120 , pp. 327-335
    • Chakraborty, A.K.1    Welsh, A.2    Digiovanna, M.P.3
  • 9
    • 84863900275 scopus 로고    scopus 로고
    • Insulin-like growth factor receptor inhibitors: baby or the bathwater?
    • Yee D Insulin-like growth factor receptor inhibitors: baby or the bathwater?. J Natl Cancer Inst 2012, 104:975-981.
    • (2012) J Natl Cancer Inst , vol.104 , pp. 975-981
    • Yee, D.1
  • 10
    • 51349091290 scopus 로고    scopus 로고
    • The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy
    • abstr 3511.
    • Di Cosimo S, Scaltriti M, Val D, et al. The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy. Proc Am Soc Clin Oncol 2007, 25(suppl). abstr 3511.
    • (2007) Proc Am Soc Clin Oncol , vol.25 , Issue.SUPPL.
    • Di Cosimo, S.1    Scaltriti, M.2    Val, D.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.